During the past years, immune checkpoint inhibitors suppressing the PD-1/PD-L1 pathway improved prognosis in different tumor entities significantly and became first line treatment in metastatic melanoma, NSCLC, HNSCC, renal and bladder cancer (4, 5, 16–18). Here, CD274 is linked to urinary bladder carcinoma.